Company Overview of Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors of viral replication enzymes that are essential to viral replication. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus, Influenza virus, Rhinovirus, Dengue Virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of various types, including non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepa...
19805 North Creek Parkway
Bothell, WA 98011
Founded in 2007
Key Executives for Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. does not have any Key Executives recorded.
Cocrystal Pharma, Inc. Key Developments
Cocrystal Pharma, Inc. Proposes Amendments to the Company's Certificate of Incorporation
Jan 7 15
Cocrystal Pharma, Inc. proposed at its EGM to be held on March 3, 2015, the shareholders to be approved that the amendments to the company's Certificate of Incorporation to increase the number of authorized shares of common stock from 200 million to 800 million shares.
Cocrystal Pharma, Inc. Announces Resignation of Roger Kornberg and Sam Lee from the Board of Directors
Nov 28 14
Cocrystal Pharma, Inc. announced that on November 22, 2014, Dr. Roger Kornberg and Dr. Sam Lee resigned from the board of directors of the company.
Cocrystal Pharma, Inc. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 14 14
Cocrystal Pharma, Inc. reported financial results for the third quarter and nine months ended September 30, 2014. During the three months period ended September 30, 2014, the company had a loss from operations of $1.2 million.
During the nine months period ended September 30, 2014, the company had a loss from operations of $4.1 million. Cash used in operating activities was approximately $4.2 million for the nine months ended September 30, 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions